<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23965" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Levodopa (L-Dopa)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gandhi</surname>
            <given-names>Kavita R.</given-names>
          </name>
          <aff>American University of Antigua</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kavita Gandhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23965.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Levodopa is the precursor to dopamine. Most commonly, clinicians use levodopa as a dopamine replacement agent for the treatment of Parkinson disease. It is most effectively used to control bradykinetic symptoms apparent in Parkinson disease. Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication. This activity covers levodopa, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, and monitoring, and highlights the role of the interprofessional team in the management of conditions where levodopa therapy is helpful.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for initiating levodopa therapy.</p></list-item><list-item><p>Describe the mechanism of levodopa as it pertains to parkinsonism and related conditions.</p></list-item><list-item><p>Review the contraindications for levodopa.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance levodopa and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23965&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23965">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23965.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Levodopa is the precursor to dopamine. Most commonly, clinicians use levodopa as a dopamine replacement agent for the treatment of Parkinson disease. It is most effectively used to control bradykinetic symptoms that are apparent in&#x000a0;Parkinson disease, and it is the most effective medication to improve the quality of life in patients with idiopathic Parkinson disease.&#x000a0;Levodopa is typically prescribed to a patient with&#x000a0;Parkinson disease&#x000a0;once symptoms become more difficult to control with other antiparkinsonian drugs. The drug is also useful for post-encephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication.<xref ref-type="bibr" rid="article-23965.r1">[1]</xref><xref ref-type="bibr" rid="article-23965.r2">[2]</xref><xref ref-type="bibr" rid="article-23965.r3">[3]</xref></p>
        <p>Recent data have suggested that levodopa can either slow down the progression of Parkinson disease and/or have increased benefits even after drug administration has stopped. A common off-label use for levodopa is restless leg syndrome and periodic limb movement in sleep (PLMS).&#x000a0;Levodopa has been suggested as a reasonable treatment option for intermittent restless leg syndrome patients who do not need regular daily therapy.<xref ref-type="bibr" rid="article-23965.r4">[4]</xref></p>
      </sec>
      <sec id="article-23965.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Degeneration of the substantia nigra occurs in patients with Parkinson disease. This condition results in the disruption of the nigrostriatal pathway and thus decreases the striatal dopamine levels. Unlike dopamine, levodopa can cross the blood-brain barrier (BBB). Levodopa converts to dopamine in both the CNS and periphery.<xref ref-type="bibr" rid="article-23965.r5">[5]</xref>&#x000a0;To increase the bioavailability of levodopa and decrease its side effects, it is often administered in combination with peripheral decarboxylase inhibitors&#x000a0;(such as carbidopa and benserazide). Dopamine decarboxylase inhibitors prevent the conversion of levodopa to dopamine in the periphery, allowing for more levodopa to cross the BBB. Once converted to dopamine, it activates postsynaptic dopaminergic receptors and compensates for the decrease in endogenous dopamine.<xref ref-type="bibr" rid="article-23965.r6">[6]</xref></p>
      </sec>
      <sec id="article-23965.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Oral:</bold> usually available in combination with carbidopa or benserazide.</p>
        <list list-type="bullet">
          <list-item>
            <p>Immediate-release (IR) tablets</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Disintegrating tablets&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Controlled-release (CR) tablets</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Extended-release (ER) capsules<xref ref-type="bibr" rid="article-23965.r7">[7]</xref><xref ref-type="bibr" rid="article-23965.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>Treatment should begin with small doses, and the recommended dose is 300 to 1200 mg (higher if tolerated) per day, divided into 3 to 12 doses.<xref ref-type="bibr" rid="article-23965.r9">[9]</xref>&#x000a0;The&#x000a0;recommended&#x000a0;titration&#x000a0;schedule is to increase the dose by 100 mg every 3&#x000a0;or 4 days.&#x000a0;Patients should take the oral form of levodopa with meals to decrease gastrointestinal (GI) upset.&#x000a0;To improve absorption, patients should take levodopa 1 hour before or 2 hours after meals containing protein.<xref ref-type="bibr" rid="article-23965.r10">[10]</xref>&#x000a0;Patients should avoid high-fat, high-calorie meals when taking levodopa as it can delay absorption by 2 hours. Also, high protein diets can decrease the amount of levodopa absorbed due to competition with amino acid transporters. The orally disintegrating tablets need to be dissolved entirely on the tongue before swallowing. The extended-release capsule of levodopa can be administered with or without food. Patients who have trouble swallowing can open up the capsule, sprinkle the contents over food, and consume it immediately.</p>
        <p><bold>Oral Inhalation:&#x000a0;</bold>Inhaled formulation of levodopa was approved by the U.S. Food and Drug Administration in 2018 to treat Parkinson disease as adjunctive therapy to levodopa/carbidopa. Inhaled levodopa bypasses the intestinal absorption and hepatic metabolism of oral levodopa, and it is available in the form of dry powder.<xref ref-type="bibr" rid="article-23965.r11">[11]</xref></p>
        <p><bold>Infusion:</bold> another form of administration is a 16-hour infusion through a nasojejunal tube. Research has shown that levodopa infusion is associated with low plasma trough levels seen with oral drug administration. Recent studies of such infusion have been shown to decrease the adverse effects of motor complications. Some studies have even shown that the pulsatile administration of levodopa can cause more motor complications than the continuous administration of the drug. Administration of levodopa in the pediatric population does not have much research, and as a result, it is not recommended to be administered to patients under the age of 18.</p>
      </sec>
      <sec id="article-23965.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The common adverse effects of Levodopa treatment are nausea, dizziness, headache, and somnolence.&#x000a0;Increasing carbidopa is recommended to relieve nausea, and domperidone can be helpful if additional carbidopa is ineffective.&#x000a0;Special precaution is necessary for elderly patients because they may be more sensitive to the central nervous system (CNS) effects. The most common side effects in older patients taking levodopa can be confusion, hallucinations, delusions, psychosis, and agitation.<xref ref-type="bibr" rid="article-23965.r12">[12]</xref><xref ref-type="bibr" rid="article-23965.r13">[13]</xref><xref ref-type="bibr" rid="article-23965.r14">[14]</xref>&#x000a0;There may be a greater risk of hip fractures in older adults due to levodopa mildly increasing homocysteine levels as an adverse effect. Patients presenting with an idiopathic parkinsonian disorder and who are on levodopa can also develop low serum vitamin B12, elevated methylmalonic acid levels, and greater chances of sensorimotor peripheral neuropathy.&#x000a0;</p>
        <p>Abrupt withdrawal or dose reduction of levodopa is associated with an increased risk of neuroleptic malignant syndrome (NMS). This condition has been termed parkinsonism hyperpyrexia syndrome.&#x000a0;Hyperthermia, involuntary movements, and muscle rigidity are seen in severe cases. Management includes replacing levodopa at the prior doses and aggressive supportive care in an intensive care unit.<xref ref-type="bibr" rid="article-23965.r15">[15]</xref></p>
        <p>The most common cardiovascular effects are dizziness and postural hypotension; thus, reducing or discontinuing antihypertensive medications is required for some patients.&#x000a0;Researchers also report cardiac arrhythmias in studies. Somnolence is another adverse effect reported with levodopa use. The onset is rapid and without warning, and thus, precaution is needed when operating motor vehicles.<xref ref-type="bibr" rid="article-23965.r16">[16]</xref>&#x000a0;Clinicians should discontinue the medication in patients that experience excessive daytime sleepiness. Long-term use of levodopa presents&#x000a0;can lead to other complications. The patients' quality of life can be negatively affected because of irreversible motor function changes from drug use.&#x000a0;These motor complications present in about 50% of patients using levodopa for 5 to 10 years. The motor complications increase depending on whether the onset of Parkinson disease was at an early age.</p>
      </sec>
      <sec id="article-23965.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The use of levodopa is contraindicated with the concurrent use of monoamine oxidase inhibitors (MAOIs) because it can lead to a hypertensive crisis. There should be a 14-day washout period when switching from levodopa to an MAOI or vice versa. Patients taking D2 antagonists may see a reduction in the effects of levodopa, and as a result, it may reduce the beneficial effects of the drug. Individuals with narrow-angle glaucoma should use levodopa with caution as it can increase ocular pressure. Extra precaution is necessary for patients with atrial nodal or ventricular arrhythmias. The recommendation is that these patients be administered levodopa in a coronary care unit. Levodopa use is also contraindicated in people with pre-existing neuropathy because symptoms have the potential to worsen. The risk of GI bleeds increases in patients who already have a history of peptic ulcer disease. Levodopa can increase the risk of psychosis in patients already diagnosed with a major psychotic disorder.</p>
        <p>Per the Food and Drug Administration (FDA)&#x000a0; label, Levodopa should not be used&#x000a0;in patients with a history of malignant melanoma due to the risk of activating melanoma. However, several studies suggested drug exposure is not the reason for the increased risk of melanoma but&#x000a0;may reflect the association of Parkinson disease with&#x000a0;melanoma. More studies are required to verify the correlation between levodopa and dermatologic effects.<xref ref-type="bibr" rid="article-23965.r17">[17]</xref></p>
      </sec>
      <sec id="article-23965.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Frequent monitoring of BUN, creatinine levels, and hepatic function is necessary for individuals taking levodopa. Good hepatic function is crucial in patients taking levodopa because it is where the drug is decarboxylated. Also, it is essential to test for intraocular pressure in patients with glaucoma. Testing patients for peripheral neuropathy before and while on levodopa is also necessary. Patients should also have regular monitoring of dyskinesia. Patients need to be observed for psychotic behavior and hallucinations while taking dopaminergic medications. Hallucinations can accompany confusion and excessive dreaming. Thus, patients with a history of past psychiatric disorders should not receive treatment with levodopa. As an extra precaution, patients require monitoring for melanoma. It is unknown whether the risk of melanoma increases due to levodopa use or Parkinson disease.</p>
      </sec>
      <sec id="article-23965.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Studies have shown that levodopa toxicity can damage neuronal cells. The formation of free radicals once the body oxidizes levodopa can induce apoptosis. Also, dopamine, norepinephrine, and epinephrine levels can rise in the blood when levodopa undergoes decarboxylation in the periphery. The rise in catecholamines activates alpha and beta-adrenergic receptors and results in toxic effects. In pregnant women, levodopa does cross the placenta and can potentially be metabolized by the fetus. Unfortunately, there is insufficient information to make an appropriate decision regarding the use of levodopa in pregnant women. The drug is excreted in breast milk, and thus, caution is advised when administering the medication to nursing women. Supportive measures are necessary to treat toxicity, such as gastric lavage, maintenance of airways, and administering intravenous (IV) fluids.</p>
      </sec>
      <sec id="article-23965.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While the initial treatment of a patient with Parkinson disease is by a neurologist, outpatient monitoring and continued care are often accomplished by the primary care provider or nurse practitioner/physician assistant; these and other caregivers need to function as an interprofessional team when managing patients on levodopa therapy. When patients start on L-dopa,&#x000a0;Frequent monitoring of BUN, creatinine levels, and hepatic function is necessary. Additionally, the patient must obtain a referral to the ophthalmologist for glaucoma screening. Patients on L dopa&#x000a0;may develop mood changes and should be closely followed by a mental health nurse.</p>
        <p>The primary care provider needs to know the Parkinson disease symptoms because L-dopa usually works for a short period, and patients may have to start on other medications. This situation is where ongoing monitoring by nursing can inform the clinician promptly of status changes so that additional interventions can commence. Also, the pharmacist should verify potential drug-drug interactions and dosing and consult with the clinician as more agents may be needed. Also, patients with Parkinson disease may develop a variety of autonomic symptoms and may need a referral to a gastroenterologist and urologist. Overall, there is no cure for Parkinson disease, and eventually, most patients succumb to the disorder, but interprofessional teamwork can optimize the outcome within these limitations.<xref ref-type="bibr" rid="article-23965.r18">[18]</xref><xref ref-type="bibr" rid="article-23965.r19">[19]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-23965.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23965&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23965">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23965/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23965">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23965.s11">
        <title>References</title>
        <ref id="article-23965.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corvol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>[Therapeutic and pharmacologic perspectives in Parkinson's disease].</article-title>
            <source>Rev Prat</source>
            <year>2018</year>
            <month>May</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>515</fpage>
            <page-range>515-519</page-range>
            <pub-id pub-id-type="pmid">30869416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebada</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alkanj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ebada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdelkarim</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Diab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>MAE</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fayed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bahbah</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Negida</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.</article-title>
            <source>CNS Neurol Disord Drug Targets</source>
            <year>2019</year>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-325</page-range>
            <pub-id pub-id-type="pmid">30868968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romagnolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Artusi</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rizzone</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Zibetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopiano</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Levodopa-Induced Neuropathy: A Systematic Review.</article-title>
            <source>Mov Disord Clin Pract</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-103</page-range>
            <pub-id pub-id-type="pmid">30838307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aurora</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Kristo</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bista</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lamm</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>RS</given-names>
              </name>
              <collab>American Academy of Sleep Medicine</collab>
            </person-group>
            <article-title>The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>Sleep</source>
            <year>2012</year>
            <month>Aug</month>
            <day>01</day>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1039</fpage>
            <page-range>1039-62</page-range>
            <pub-id pub-id-type="pmid">22851801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reich</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Savitt</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Parkinson's Disease.</article-title>
            <source>Med Clin North Am</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>337</fpage>
            <page-range>337-350</page-range>
            <pub-id pub-id-type="pmid">30704685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogungbenro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pertinez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aarons</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying.</article-title>
            <source>AAPS J</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>227</fpage>
            <page-range>227-36</page-range>
            <pub-id pub-id-type="pmid">25413723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreitzman</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Apr</month>
            <day>05</day>
            <volume>86</volume>
            <issue>14 Suppl 1</issue>
            <fpage>S13</fpage>
            <page-range>S13-24</page-range>
            <pub-id pub-id-type="pmid">27044646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ondo</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Shinawi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.</article-title>
            <source>Mov Disord</source>
            <year>2010</year>
            <month>Dec</month>
            <day>15</day>
            <volume>25</volume>
            <issue>16</issue>
            <fpage>2724</fpage>
            <page-range>2724-7</page-range>
            <pub-id pub-id-type="pmid">20925074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jog</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>An update on the diagnosis and treatment of Parkinson disease.</article-title>
            <source>CMAJ</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>188</volume>
            <issue>16</issue>
            <fpage>1157</fpage>
            <page-range>1157-1165</page-range>
            <pub-id pub-id-type="pmid">27221269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>F</given-names>
              </name>
              <collab>Parkinson Society Canada</collab>
            </person-group>
            <article-title>Parkinson's disease guidelines for pharmacists.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2014</year>
            <month>May</month>
            <volume>147</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-70</page-range>
            <pub-id pub-id-type="pmid">24847369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LeWitt</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Pahwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saint-Hilaire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pourcher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lopez-Manzanares</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudz&#x000ed;nska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sedkov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Batycky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>C</given-names>
              </name>
              <collab>SPAN-PD Study Investigators</collab>
            </person-group>
            <article-title>Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.</article-title>
            <source>Lancet Neurol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-154</page-range>
            <pub-id pub-id-type="pmid">30663606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trenkwalder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuoppam&#x000e4;ki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vahteristo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ellm&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Mar</month>
            <day>26</day>
            <volume>92</volume>
            <issue>13</issue>
            <fpage>e1487</fpage>
            <page-range>e1487-e1496</page-range>
            <pub-id pub-id-type="pmid">30824559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poewe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.</article-title>
            <source>Neurodegener Dis Manag</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">30547712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Jimenez-Shahed</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>2955</fpage>
            <page-range>2955-2964</page-range>
            <pub-id pub-id-type="pmid">30464480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Grosset</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>The parkinsonism-hyperpyrexia syndrome.</article-title>
            <source>Neurocrit Care</source>
            <year>2009</year>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-40</page-range>
            <pub-id pub-id-type="pmid">18712508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalinderi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Papaliagkas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fidani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics and levodopa induced motor complications.</article-title>
            <source>Int J Neurosci</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>384</fpage>
            <page-range>384-392</page-range>
            <pub-id pub-id-type="pmid">30359152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bougea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spantideas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Katoulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stefanis</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-336</page-range>
            <pub-id pub-id-type="pmid">31338806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabbri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosa</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.</article-title>
            <source>Drugs Aging</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1041</fpage>
            <page-range>1041-1054</page-range>
            <pub-id pub-id-type="pmid">30318555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23965.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Classen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koschel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oehlwein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seppi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>W&#x000fc;llner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>124</volume>
            <issue>8</issue>
            <fpage>1029</fpage>
            <page-range>1029-1036</page-range>
            <pub-id pub-id-type="pmid">28702850</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
